Global pharma major Lupin Ltd. has announced its inclusion in the S&P Global Sustainability Yearbook 2025, for the second consecutive year. This recognition highlights Lupin’s exceptional performance and dedication to sustainability.

Lupin has been included in the Top 10 percent S&P Global CSA Score – which refers to companies that rank within the top 10 percent of their industry, based on their Corporate Sustainability Assessment (CSA) Score for 2024.

Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment (CSA) score. Lupin's S&P Global CSA score has significantly improved, from 65 to 75, in 2024. This year, 7,690 companies assessed in the 2024 CSA were considered for the 2025 Sustainability Yearbook, out of which only 780 companies across 62 industries were recognised.

Commenting on the achievement, Ramesh Swaminathan, Executive Director, Global CFO and Head – API Plus SBU, Lupin said, “Being featured in the S&P Global Sustainability Yearbook for the second consecutive year underscores our unwavering commitment to sustainability. We are at the forefront of the pharmaceutical industry in promoting sustainable business practices globally. We remain committed to advancing impactful initiatives that support a sustainable and equitable future for our patients, communities, and stakeholders worldwide.”

Lupin is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specialises in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company enjoys a strong position in India and the US across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centres globally.